Targeting the glucocorticoid receptor for a combinatory treatment strategy for castration resistant prostate cancer?

Abstract

Prostate cancer (PCa) ranks the most frequently diagnosed male cancer in the Western world (1). It develops first as an androgen-dependent tumor in which androgens promote the growth of the PCa cells. Eventually, it develops into a castration resistant stage that no longer depends on androgens.